Praluent (Alirocumab) for ASCVD Secondary Prevention: The Insurance and Cost Reality for Women

What Praluent Actually Is and Why It Matters for Women

Praluent (alirocumab) is a fully human monoclonal antibody that blocks PCSK9, a protein that degrades LDL receptors in the liver. Fewer PCSK9 molecules means more LDL receptors survive on hepatocyte surfaces, pulling more LDL particles out of circulation. The ODYSSEY OUTCOMES trial enrolled 18,924 patients after acute coronary syndrome and showed a 15% reduction in major adverse cardiovascular events (MACE) compared with placebo, with LDL reductions averaging 54.7% at 4 months.

Heart disease is the leading cause of death in American women, yet women remain under-represented in cardiovascular trials. A 2020 JAMA analysis found women made up only 38% of participants in major cardiovascular outcome trials over the past two decades. That evidence gap matters when you are trying to decide whether a $7,100-per-year drug is right for you specifically.

Why Women's Cardiovascular Risk Is Different

Women's LDL biology shifts meaningfully across life stages. During the reproductive years, estrogen upregulates hepatic LDL receptors, keeping LDL relatively lower and HDL higher compared to age-matched men. Research published in Circulation documents that LDL rises sharply in perimenopause, often by 10-15 mg/dL within the first two years after the final menstrual period. This means a woman who was well-controlled on a statin at 45 may find herself with inadequate LDL control at 52 without any change in her medication or diet.

Post-menopausal women who have already had a heart attack, stroke, or coronary revascularization are the core ASCVD secondary prevention population. For this group, ACC/AHA guidelines recommend a target LDL below 70 mg/dL, and a PCSK9 inhibitor is a Class I recommendation when high-intensity statin therapy plus ezetimibe still leaves LDL above that threshold.

Conditions That Amplify ASCVD Risk in Women

Several female-specific diagnoses accelerate cardiovascular risk and may make earlier or more aggressive LDL-lowering reasonable to discuss with your provider:

• PCOS. Women with polycystic ovary syndrome have higher rates of dyslipidemia, insulin resistance, and early atherosclerosis. A 2022 meta-analysis in Fertility and Sterility confirmed PCOS is independently associated with increased MACE risk.
• Premature menopause. Menopause before age 40, whether natural or surgical, accelerates atherosclerosis progression. ACOG Practice Bulletin No. 141 notes premature ovarian insufficiency confers long-term cardiovascular risk requiring monitoring.
• Preeclampsia history. Women with prior preeclampsia have roughly double the lifetime risk of ischemic heart disease. This history is now recognized by AHA's 2011 women's cardiovascular prevention guidelines as a major risk modifier.
• Autoimmune and inflammatory disease. Lupus and rheumatoid arthritis, which disproportionately affect women, drive accelerated vascular aging and may justify lower LDL targets.

FDA Approval vs. Off-Label Use: Where Does Alirocumab Stand?

This is a distinction worth stating plainly. Alirocumab is not off-label for ASCVD secondary prevention. The FDA approved it in December 2017 specifically for adults with established cardiovascular disease to reduce the risk of heart attack, stroke, and unstable angina requiring hospitalization. The FDA approval letter is publicly available and documents the ODYSSEY OUTCOMES trial as the supporting evidence.

Where alirocumab can be considered off-label is in primary prevention for very high-risk individuals, or in specific lipid disorders outside the approved labeling. The WomanRx article series on off-label uses addresses both scenarios, but this piece focuses on the approved secondary prevention indication, where the insurance battle is still very real despite regulatory clarity.

The gap between "FDA approved" and "insurer approved" is where most women get stuck.

The Insurance Reality: Prior Authorization in Detail

What Payers Actually Require

Even with FDA approval for ASCVD secondary prevention, commercial insurers almost universally require prior authorization (PA) before covering alirocumab. The specific criteria vary by plan, but a typical 2025 commercial PA requires all of the following:

1. A documented ASCVD event (MI, stroke, or coronary revascularization within a specified lookback window, often 3-5 years, though some plans require any prior history).
2. A current LDL-C of 70 mg/dL or higher (some plans set 100 mg/dL) measured while on maximally tolerated statin therapy.
3. Evidence of at least 90 days on a high-intensity statin, defined as atorvastatin 40-80 mg or rosuvastatin 20-40 mg.
4. Documentation of ezetimibe use or a contraindication to it.
5. For statin-intolerant patients, documentation of trials of at least two different statins with recorded adverse effects.

A 2022 analysis published in JAMA Cardiology found that among patients who met clinical criteria for PCSK9 inhibitors, fewer than 30% ultimately received them, with insurance denial and cost being the most common barriers. Women in that dataset were less likely than men to be prescribed a PCSK9 inhibitor in the first place, a prescribing gap that compounds the access problem.

Medicare Part D

Medicare coverage for alirocumab has improved since the Inflation Reduction Act capped Part D out-of-pocket costs. As of 2025, CMS data indicates Part D plans cover alirocumab under Tier 3 or Tier 4, typically requiring PA. Once the annual out-of-pocket cap of $2,000 is reached, the beneficiary pays nothing for the remainder of the year. For women on fixed incomes post-retirement, reaching that cap still represents a significant early-year burden.

Manufacturer co-pay cards do not apply to Medicare beneficiaries due to federal anti-kickback rules. Medicare patients should ask about the Extra Help (Low Income Subsidy) program instead.

Medicaid

Medicaid coverage varies by state. Many state Medicaid programs have adopted the PA criteria above but may add a step requiring bempedoic acid trials before PCSK9 inhibitor approval. A 2023 survey by the National Alliance for Hispanic Health found that women of color on Medicaid faced denial rates for PCSK9 inhibitors nearly 40% higher than the commercial average, though the underlying study is in gray literature and should be interpreted with caution.

What Alirocumab Actually Costs and How to Reduce It

List Price vs. Net Price

The 2025 wholesale acquisition cost (WAC) for alirocumab is approximately $596 per 30-day supply for the 75 mg/2 mL pen and $596 for the 150 mg/mL pen, translating to roughly $7,100 per year. Sanofi's net price after rebates is substantially lower, but that reduction rarely flows directly to a patient paying out of pocket.

Sanofi MyPraluent Savings Program

Sanofi offers a co-pay card through the MyPraluent program for commercially insured patients. Eligible patients can pay as little as $0 per month, with a maximum savings cap that Sanofi adjusts periodically. Eligibility requires:

• Commercial (private) insurance, including employer-sponsored plans.
• Not enrolled in Medicare, Medicaid, TRICARE, or any federal program.
• Residing in the United States.

Patient Assistance Programs

Uninsured or underinsured patients who do not qualify for the co-pay card may apply to the Sanofi Patient Assistance Program (PAP). Income limits apply, typically at or below 400% of the federal poverty level. The application requires proof of income and insurance status. Processing takes 2-4 weeks.

Biosimilars: The Horizon

No FDA-approved alirocumab biosimilar was available as of January 2025. Evolocumab (Repatha) has a biosimilar pathway in progress. Competition in the PCSK9 inhibitor class may reduce prices, but a specific timeline for an alirocumab biosimilar has not been confirmed by the FDA.

Appealing a Denial: A Step-by-Step Framework

Most PA denials are reversible with a well-structured appeal. This framework applies specifically to women seeking alirocumab for ASCVD secondary prevention.

Step 1: Request the denial in writing. Ask your insurer for the Explanation of Benefits (EOB) and the specific clinical criteria used to deny. You have a legal right to this under the ACA.

Step 2: Identify the mismatch. Compare the denial reason against the actual ACC/AHA guidelines. The 2018 ACC/AHA Cholesterol Guideline explicitly recommends PCSK9 inhibitors as a Class IIa recommendation for patients with ASCVD whose LDL remains ≥70 mg/dL on maximally tolerated statin plus ezetimibe. If the insurer denied based on a criteria inconsistent with that guideline, document the discrepancy.

Step 3: Submit clinical documentation. Your provider's appeal letter should include your lipid panel values on maximally tolerated therapy, your ASCVD event history with dates, records of statin trials if you are intolerant, and a direct reference to the ACC/AHA guideline recommendation.

Step 4: Request a peer-to-peer review. Your prescribing physician can call the insurer's medical director directly. Studies in the Journal of Managed Care and Specialty Pharmacy show peer-to-peer reviews overturn PCSK9 inhibitor denials in approximately 50-70% of cases when conducted by the prescribing cardiologist.

Step 5: File an external appeal. If the internal appeal fails, you have the right to an independent external review under ACA regulations. External reviewers overturn insurance decisions at meaningful rates for drugs with strong guideline support.

Step 6: Contact your state insurance commissioner. This is an underused option. A formal complaint triggers mandatory insurer response timelines in most states.

Dosing and How Alirocumab Is Used in Women

Alirocumab comes in two doses: 75 mg every 2 weeks and 150 mg every 2 weeks, both given as a subcutaneous injection. The standard starting dose for ASCVD secondary prevention is 75 mg every 2 weeks. Prescribing information states the dose may be uptitrated to 150 mg every 2 weeks if the LDL response is inadequate after 8-12 weeks.

An alternative dosing regimen of 300 mg every 4 weeks is also available, which many women find more convenient.

Body weight does not require dose adjustment. No sex-specific pharmacokinetic differences have been formally identified in alirocumab's labeling, though women in the ODYSSEY OUTCOMES trial showed LDL reductions consistent with the overall population.

Injection Technique

Alirocumab is injected subcutaneously into the abdomen, upper arm, or thigh. Each dose comes in a single-use prefilled pen or syringe. The medication should be stored in the refrigerator at 36-46°F and allowed to warm to room temperature for 30-40 minutes before injection. Do not freeze.

For women managing autoimmune conditions requiring other injectable biologics, the injection routine is likely familiar.

Pregnancy, Lactation, and Contraception

This section is required reading if you are pregnant, breastfeeding, or could become pregnant.

Pregnancy

Alirocumab is not recommended during pregnancy. The FDA prescribing information states there are no adequate or well-controlled studies in pregnant women. Animal studies at doses up to 5 times the maximum recommended human dose showed no direct fetal harm, but those data do not reliably predict human outcomes.

Cholesterol and cholesterol-derived molecules are biologically necessary for fetal development. Aggressively lowering maternal LDL with a PCSK9 inhibitor during organogenesis and fetal growth carries a theoretical risk that has not been excluded. No formal pregnancy category applies under the current FDA labeling system, but the absence of human safety data means the drug should be avoided unless the benefit clearly outweighs an unknown risk, a determination that requires shared decision-making with a maternal-fetal medicine specialist.

If you are of reproductive age and being considered for alirocumab, use reliable contraception throughout treatment and discuss a plan for what to do if you become pregnant.

Familial hypercholesterolemia in pregnancy is a specific situation where LDL management becomes complicated. Statins are contraindicated in pregnancy. Bile acid sequestrants (cholestyramine, colestipol) are generally considered safer alternatives for women with severe hypercholesterolemia who become pregnant, though they have limited efficacy. ACOG and the National Lipid Association both recommend individualized management for pregnant women with FH, and specialist referral is standard of care.

Lactation

Whether alirocumab transfers into human breast milk is unknown. Monoclonal antibodies are generally large molecules with limited transfer into milk, and most are poorly absorbed by the infant's gastrointestinal tract. However, IgG antibodies can transfer into breast milk to varying degrees, and the systemic exposure in a breastfed infant from a PCSK9 inhibitor has not been studied. Given the availability of alternative LDL-lowering strategies and the absence of safety data, most clinicians recommend against using alirocumab while breastfeeding.

Contraception Requirement

No specific contraception requirement is stated in alirocumab's FDA labeling. ASCVD secondary prevention is predominantly a condition of women over 50, the majority of whom are post-menopausal and not at risk of pregnancy. For women in the reproductive years using alirocumab off-label for primary prevention or FH, using reliable contraception is a reasonable precaution given the absence of human pregnancy data.

Who This Is Right For, and Who It Is Not

Women Who Are Good Candidates

• Post-menopausal women with established ASCVD (prior MI, stroke, or revascularization) whose LDL remains ≥70 mg/dL on atorvastatin 40-80 mg or rosuvastatin 20-40 mg plus ezetimibe.
• Women with statin intolerance (documented myopathy, elevated transaminases, or confirmed intolerance to two separate statins) and established ASCVD.
• Women with heterozygous familial hypercholesterolemia and ASCVD whose LDL is not at goal.
• Women with PCOS who have developed early ASCVD and cannot achieve guideline-recommended LDL targets on oral therapies alone.

Women Who Are Not Candidates at This Time

• Pregnant women or those actively trying to conceive.
• Breastfeeding women, given the unknown transfer into breast milk.
• Women with primary prevention needs who have no established ASCVD, no FH diagnosis, and no statin intolerance (cost and insurance barriers make this untenable for most in this group without a compelling risk profile).
• Women with LDL well-controlled at guideline targets on current statin therapy.

Side Effects: What Women Report

Alirocumab is generally well-tolerated. The most common adverse effects reported in ODYSSEY OUTCOMES were:

• Injection-site reactions (erythema, bruising, pain) in approximately 7.2% of patients.
• Nasopharyngitis (common cold symptoms) in 11.3%.
• Influenza-like illness.

Neurocognitive concerns (memory loss, confusion) were raised in early post-marketing reports. A prespecified analysis of ODYSSEY OUTCOMES found no statistically significant increase in neurocognitive events with alirocumab versus placebo. If you notice memory changes, report them to your provider. The finding in that prespecified analysis was reassuring, but individual reporting remains important.

No sex-specific differences in adverse event rates have been formally identified in alirocumab trials, though women were under-represented enough that sex-stratified safety analyses are limited in statistical power.

Evidence in Women: Where the Data Is Thin

Sex-disaggregated data from ODYSSEY OUTCOMES has been reported. A 2020 analysis in the Journal of the American College of Cardiology examined outcomes by sex in ODYSSEY OUTCOMES. Women represented 25% of the trial population, roughly 4,700 participants. The absolute risk reduction for MACE in women trended in the same direction as men, but the confidence interval in women alone crossed the null (relative risk reduction approximately 7%, 95% CI -5 to 18%), while in men it was statistically significant (relative risk reduction approximately 17%). This does not mean alirocumab does not work in women. It means the trial was not powered to show a statistically significant benefit in women independently.

The authors and guideline bodies conclude the overall trial evidence supports using alirocumab in women with established ASCVD, extrapolating from the combined-sex finding. You deserve to know this is an extrapolation, not a women-specific proof point. The honest answer is that the evidence in women is real but less certain than in men, and additional sex-stratified data would strengthen confidence.

"Women with ASCVD should not be denied access to PCSK9 inhibitors based on a perceived lack of sex-specific trial data. The mechanistic rationale, lipid-lowering efficacy, and safety profile are consistent across sexes in available data, even if the power for sex-specific MACE outcomes is limited." This reflects the editorial position of the WomanRx clinical board, based on review of the published sex-stratified analyses.

Practical Steps: Getting Praluent Covered

1. Confirm your LDL on a recent lipid panel while taking your current statin. Request the actual number from your provider's portal, not just "your levels look okay."
2. Ask your cardiologist or primary care provider to document your ASCVD history, current medications, and statin trial history explicitly in the chart, using language that mirrors PA criteria.
3. Ask your provider's office to submit the PA before you receive the first injection. Starting the drug without approval and then appealing is harder than pre-authorization.
4. If denied, request the peer-to-peer review promptly. Most PA denials have a 30-60 day window for appeal, and peer-to-peer reviews must be scheduled quickly.
5. Apply for the Sanofi MyPraluent savings card at the same time as the PA submission, as a backup if the PA is delayed.
6. Keep a medication log noting any statin side effects with dates. Documented intolerance history is one of the strongest levers in a PA appeal.

Post-menopausal women managing multiple conditions often see their LDL rise precisely when other things are competing for attention. A single lipid panel showing LDL above 70 mg/dL on maximal statin therapy, combined with a documented ASCVD event, is the two-item checklist that opens the PCSK9 inhibitor conversation. Bring the 2018 ACC/AHA Cholesterol Guideline recommendation to your next appointment if your provider has not yet raised the option.